BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
2.540
+0.290 (12.89%)
Mar 17, 2026, 4:00 PM EDT - Market closed

BioNexus Gene Lab Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
5509165365-
Market Cap Growth
-22.50%437.27%-94.33%-54.77%--
Enterprise Value
1.8346.093.53162.95362.750
Last Close Price
2.542.805.30114.00255.70-
PE Ratio
--31.11-31.93-247.83532.71-
PS Ratio
0.475.290.9615.1027.30-
PB Ratio
0.596.040.9724.7650.81-
P/TBV Ratio
8.156.008.7124.6550.82-
P/FCF Ratio
--20.44-4.75331.6260816.32-
P/OCF Ratio
--22.52-5.14299.0739825.03-
EV/Sales Ratio
0.194.850.3614.9127.15-
EV/EBITDA Ratio
--32.45-1.42-877.24311.63-
EV/EBIT Ratio
--29.29-1.36-559.64343.57-
EV/FCF Ratio
--18.73-1.79327.4560468.52-
Debt / Equity Ratio
0.020.020.010.010.010.01
Debt / EBITDA Ratio
-0.08-0.15-0.05-0.310.070.09
Debt / FCF Ratio
-0.06-0.09-0.070.1112.830.94
Net Debt / Equity Ratio
-0.40-0.50-0.60-0.31-0.28-0.40
Net Debt / EBITDA Ratio
1.242.932.3311.10-1.76-1.94
Net Debt / FCF Ratio
0.931.692.94-4.14-341.22-20.33
Asset Turnover
1.050.870.971.191.362.01
Inventory Turnover
6.736.517.987.748.2216.34
Quick Ratio
6.813.104.242.522.392.02
Current Ratio
8.303.814.933.003.072.37
Return on Equity (ROE)
-31.32%-17.74%-31.95%-5.14%10.86%28.11%
Return on Assets (ROA)
-26.01%-14.42%-25.76%-3.73%7.73%19.46%
Return on Invested Capital (ROIC)
-55.68%-38.59%-60.71%-6.81%16.14%50.02%
Return on Capital Employed (ROCE)
-30.45%-17.24%-31.43%-4.17%15.10%32.16%
Earnings Yield
-51.14%-3.21%-3.13%-0.40%0.19%-
FCF Yield
-61.48%-4.89%-21.06%0.30%0.00%-
Buyback Yield / Dilution
0.00%0.00%-61.41%-0.09%0.00%-
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q